Showing results (271-280 of 357) with videos related to
Sort By:
Pageof 36
Cancer|September 26, 1997
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumorsG T Budd, R Ganapathi, D J Adelstein, et al.Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|December 1, 1991
Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignanciesR M Bukowski, J S Sergi, G T Budd, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 1, 1994
Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effectsR M Bukowski, S A Murthy, J Finke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2008
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinomaToni K Choueiri, Anne Plantade, Paul Elson, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effectsR M Bukowski, S Murthy, D McLain, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferationJ H Finke, P Rayman, L Hart, et al.Cancer Research|August 15, 1991
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinomaR M Bukowski, W Sharfman, S Murthy, et al.Anticancer Research|July 11, 2006
Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanismsNagio Takigawa, Susan A J Vaziri, Dale R Grabowski, et al.Molecular Pharmacology|November 26, 1999
Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposideD R Grabowski, K A Holmes, M Aoyama, et al.Cancer|August 23, 2008
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Ronald M Bukowski, Robert A Figlin, et al.Pageof 36